Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ChIP-seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 39 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- MelanomaThis series is part of our curated briefing on it.
- Samples
- 39 samples: 12 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE316110_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1400616 and SRA study SRP661097. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 36 samples.
How we read this: 12 replicated groups read from 39 sample titles; they account for 36 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9444912 A375_input
- GSM9444913 A375_Ctrl_DMSO_H3K9ac_rep1 A375_Ctrl_DMSO_H3K9ac
- GSM9444914 A375_Ctrl_DMSO_H3K9ac_rep2 A375_Ctrl_DMSO_H3K9ac
- GSM9444915 A375_Ctrl_DMSO_H3K9ac_rep3 A375_Ctrl_DMSO_H3K9ac
- GSM9444916 A375_Ctrl_Vemu_H3K9ac_rep1 A375_Ctrl_Vemu_H3K9ac
- GSM9444917 A375_Ctrl_Vemu_H3K9ac_rep2 A375_Ctrl_Vemu_H3K9ac
- GSM9444918 A375_Ctrl_Vemu_H3K9ac_rep3 A375_Ctrl_Vemu_H3K9ac
- GSM9444919 A375_TADA2Bsg1_DMSO_H3K9ac_rep1 A375_TADA2Bsg1_DMSO_H3K…
- GSM9444920 A375_TADA2Bsg1_DMSO_H3K9ac_rep2 A375_TADA2Bsg1_DMSO_H3K…
- GSM9444921 A375_TADA2Bsg1_DMSO_H3K9ac_rep3 A375_TADA2Bsg1_DMSO_H3K…
- GSM9444922 A375_TADA2Bsg1_Vemu_H3K9ac_rep1 A375_TADA2Bsg1_Vemu_H3K…
- GSM9444923 A375_TADA2Bsg1_Vemu_H3K9ac_rep2 A375_TADA2Bsg1_Vemu_H3K…
- GSM9444924 A375_TADA2Bsg1_Vemu_H3K9ac_rep3 A375_TADA2Bsg1_Vemu_H3K…
- GSM9444925 A375_TADA2Bsg2_DMSO_H3K9ac_rep1 A375_TADA2Bsg2_DMSO_H3K…
- GSM9444926 A375_TADA2Bsg2_DMSO_H3K9ac_rep2 A375_TADA2Bsg2_DMSO_H3K…
- GSM9444927 A375_TADA2Bsg2_DMSO_H3K9ac_rep3 A375_TADA2Bsg2_DMSO_H3K…
- GSM9444928 A375_TADA2Bsg2_Vemu_H3K9ac_rep1 A375_TADA2Bsg2_Vemu_H3K…
- GSM9444929 A375_TADA2Bsg2_Vemu_H3K9ac_rep2 A375_TADA2Bsg2_Vemu_H3K…
- GSM9444930 A375_TADA2Bsg2_Vemu_H3K9ac_rep3 A375_TADA2Bsg2_Vemu_H3K…
- GSM9444931 A375_GCN5PCAFsg_DMSO_H3K9ac_rep1 A375_GCN5PCAFsg_DMSO_H3…
- GSM9444932 A375_GCN5PCAFsg_DMSO_H3K9ac_rep2 A375_GCN5PCAFsg_DMSO_H3…
- GSM9444933 A375_GCN5PCAFsg_DMSO_H3K9ac_rep3 A375_GCN5PCAFsg_DMSO_H3…
- GSM9444934 A375_GCN5PCAFsg_Vemu_H3K9ac_rep1 A375_GCN5PCAFsg_Vemu_H3…
- GSM9444935 A375_GCN5PCAFsg_Vemu_H3K9ac_rep2 A375_GCN5PCAFsg_Vemu_H3…
- GSM9444936 A375_GCN5PCAFsg_Vemu_H3K9ac_rep3 A375_GCN5PCAFsg_Vemu_H3…
- GSM9444937 A375_DSG_input
- GSM9444938 A375_DSG_GFPsg_GCN5_rep1 A375_DSG_GFPsg_GCN5
- GSM9444939 A375_DSG_GFPsg_GCN5_rep2 A375_DSG_GFPsg_GCN5
- GSM9444940 A375_DSG_GFPsg_GCN5_rep3 A375_DSG_GFPsg_GCN5
- GSM9444941 A375_DSG_TADA2Bsg2_GCN5_rep1 A375_DSG_TADA2Bsg2_GCN5
- GSM9444942 A375_DSG_TADA2Bsg2_GCN5_rep2 A375_DSG_TADA2Bsg2_GCN5
- GSM9444943 A375_DSG_TADA2Bsg2_GCN5_rep3 A375_DSG_TADA2Bsg2_GCN5
- GSM9444944 A375_DSG_EV
- GSM9444945 A375_DSG_DMSO_HA-TADA2B_rep1 A375_DSG_DMSO_HA-TADA2B
- GSM9444946 A375_DSG_DMSO_HA-TADA2B_rep2 A375_DSG_DMSO_HA-TADA2B
- GSM9444947 A375_DSG_DMSO_HA-TADA2B_rep3 A375_DSG_DMSO_HA-TADA2B
- GSM9444948 A375_DSG_Vemu_HA-TADA2B_rep1 A375_DSG_Vemu_HA-TADA2B
- GSM9444949 A375_DSG_Vemu_HA-TADA2B_rep2 A375_DSG_Vemu_HA-TADA2B
- GSM9444950 A375_DSG_Vemu_HA-TADA2B_rep3 A375_DSG_Vemu_HA-TADA2B
- GSE12391 Melanoma: comparison between common nevi, radial/vertical growth phase melanoma, metastases and dysplastic nevi 114 samples same disease briefing · shares melanoma
- GSE134459 Genome-wide maps of transcriptomic and epigenomic state in melanoma cell lines 73 samples same disease briefing · shares melanoma
- GSE230489 RNA-sequencing of cutaneous melanoma and non-small cell lung cancer biopsies 38 samples same disease briefing · shares melanoma
- GSE100797 Mutational and neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma 25 samples same disease briefing · shares melanoma
- GSE123728 Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma 24 samples same disease briefing · shares melanoma
- GSE130956 Investigation of ST8SIA1 expression in icaritin-treated and untreated melanoma cell lines 12 samples same disease briefing · shares melanoma
- GSE140150 A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 has a neural crest-like phenotype and is highly metastatic in vivo 6 samples same disease briefing · shares melanoma
- GSE142751 Genome-wide maps of chromatin state in 142 cancer cell lines [cell line] 855 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.